Portola Pharmaceuticals, Inc.
PTLA
PTLA was delisted on the 1st of July, 2020.
215 hedge funds and large institutions have $2.82B invested in Portola Pharmaceuticals, Inc. in 2017 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 93 increasing their positions, 55 reducing their positions, and 37 closing their positions.
69% more repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 55
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
3% less funds holding
Funds holding: 221 → 215 (-6)
10% less capital invested
Capital invested by funds: $3.12B → $2.82B (-$305M)
16% less first-time investments, than exits
New positions opened: 31 | Existing positions closed: 37
55% less call options, than puts
Call options by funds: $18.7M | Put options by funds: $41.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$43.6M |
| 2 |
Wells Fargo
San Francisco,
California
|
+$32.4M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$26.8M |
| 4 |
CCM
Cadian Capital Management
New York
|
+$18.1M |
| 5 |
BlackRock
New York
|
+$14.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$76.6M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$51.7M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$27M |
| 4 |
LCM
Laurion Capital Management
New York
|
-$24.3M |
| 5 |
Millennium Management
New York
|
-$21.9M |
PTLA Hedge Fund Activity: Q4 2017 in Review
215 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Portola Pharmaceuticals, Inc. (PTLA) for Q4 2017, worth a combined $2.82B — down 9.8% from $3.12B a quarter earlier.
Sellers outnumbered buyers: 37 funds closed out of PTLA and 31 opened new positions — a net loss of 6 holders — while 55 trimmed existing stakes and 93 added.
The largest buyer was PFM Health Sciences, adding an estimated $43.6M. The largest seller was Fidelity Investments, cutting an estimated $76.6M.
- 215 institutional investors held Portola Pharmaceuticals, Inc. (PTLA) as of Q4 2017, down from 221 in Q3 2017.
- Funds reported $2.82B of Portola Pharmaceuticals, Inc. stock for Q4 2017, down 9.8% quarter-over-quarter.
- 31 funds opened new Portola Pharmaceuticals, Inc. positions in Q4 2017 and 37 closed out, a net change of -6 holders.
- The largest Portola Pharmaceuticals, Inc. buyer in Q4 2017 was PFM Health Sciences, an estimated $43.6M added.
- The largest Portola Pharmaceuticals, Inc. seller in Q4 2017 was Fidelity Investments, an estimated $76.6M sold.
Based on aggregated 13F filings for Q4 2017.